GSK Licenses Anti-CD20 Agent; Efficacy Relative To Rituxan Touted
Executive Summary
Genmab's HuMax-CD20 could be more efficacious than Genentech/Biogen Idec's Rituxan due to the potential for greater activation of immune system defenses, the firm said Dec. 19 after announcing it had reached a codevelopment deal for ofatumumab with GlaxoSmithKline
You may also be interested in...
GSK Has 25 Potential Launches By Decade’s End; Neuroscience A Focus
GlaxoSmithKline could see 25 new drug launches in the time period from 2007 to 2009, including 12 new chemical entities, eight product line extensions and five vaccines, R&D Chairman Moncef Slaoui stated during a pipeline update with investors Dec. 13 in New York City
GSK Has 25 Potential Launches By Decade’s End; Neuroscience A Focus
GlaxoSmithKline could see 25 new drug launches in the time period from 2007 to 2009, including 12 new chemical entities, eight product line extensions and five vaccines, R&D Chairman Moncef Slaoui stated during a pipeline update with investors Dec. 13 in New York City
FDA’s “Drug Safety Newsletter” Offers Doctors Quarterly Updates On Risks
FDA's inaugural issue of its "Drug Safety Newsletter" suggests the agency will use the publication to remind doctors of potential products rather than be a primary forum for new information